GlassScriptPhysician profile
Tracy M Parker
NPI 1932243532
$18,698.66
in general payments reported to CMS, 2019-2025
54 companies · $3,182 in 2025
The $3,182 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,553 · 2022: $6,088 · 2023: $3,570 · 2024: $3,304 · 2025: $3,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,025.01 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,486.80 | 2021-2025 | Linq II, Interstim |
| Astrazeneca Pharmaceuticals LP | $1,422.37 | 2021-2025 | Wainua, Tezspire, Andexxa |
| Amgen INC. | $965.27 | 2021-2025 | Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $895.43 | 2021-2024 | Xarelto, Spravato |
| Genzyme Corporation | $832.95 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $789.09 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $732.73 | 2021-2025 | |
| Novo Nordisk INC | $622.82 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $575.97 | 2022-2025 | Epclusa |
| Alexion Pharmaceuticals, INC. | $482.32 | 2022-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $462.74 | 2021-2025 | |
| Dexcom, INC. | $384.51 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $372.21 | 2021-2024 | Nexletol, Nexlizet |
| Abbott Laboratories | $353.36 | 2022-2025 | Freestyle Libre 3, Cardiomems |
| Viiv Healthcare Company | $345.66 | 2021-2025 | Apretude |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $337.81 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $320.37 | 2021-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.30 | 2022-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.70 | 2022-2023 | Lifevest |
| Lilly USA, LLC | $261.94 | 2024-2025 | Mounjaro |
| Boston Scientific Corporation | $230.73 | 2021-2025 | Cds - Mct/Cem Monitoring, Watchman Flx |
| Phathom Pharmaceuticals, INC. | $226.65 | 2024 | Voquezna |
| Neurelis, INC. | $216.99 | 2023-2024 | Valtoco |
| Exact Sciences Corporation | $213.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ucb, INC. | $200.01 | 2023 | Nayzilam, Fintepla |
| Neurocrine Biosciences, INC. | $198.15 | 2021 | |
| Atricure, INC. | $186.76 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $185.32 | 2024 | Amvuttra, Onpattro |
| Lexicon Pharmaceuticals, INC. | $180.90 | 2023-2024 | Inpefa |
| Madrigal Pharmaceuticals | $146.52 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $145.49 | 2022-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $144.48 | 2023-2024 | |
| Edwards Lifesciences Corporation | $143.24 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.67 | 2025 | |
| Organon LLC | $137.77 | 2025 | Vtama |
| Janssen Biotech, INC. | $136.78 | 2025 | |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
| Sanofi Pasteur INC. | $124.97 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.34 | 2022 | |
| Kyowa Kirin, INC. | $120.73 | 2025 | |
| Alkermes, INC. | $120.00 | 2022 | |
| Horizon Therapeutics Plc | $113.63 | 2022 | |
| Agile Therapeutics, INC. | $111.37 | 2021 | |
| Impulse Dynamics (USA) INC. | $103.18 | 2023 | Optimizer |
| Impel Pharmaceuticals INC. | $99.99 | 2022 | |
| Nevro Corp. | $98.49 | 2022 | |
| Mannkind Corporation | $84.34 | 2022 | |
| Pfizer INC. | $84.24 | 2022-2024 | |
| Kestra Medical Technology Services, INC. | $73.50 | 2022-2023 | Assure Wcd |
| Glaxosmithkline, LLC. | $70.60 | 2024-2025 | Nucala |
| Xeris Pharmaceuticals, INC. | $20.71 | 2024 | Gvoke Hypopen |
| Phadia US INC. | $19.11 | 2025 | Immunocap |
| Seqirus USA INC | $16.44 | 2024 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.